|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating activities | |||||
| Net income | |||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||
| Share-based compensation | |||||
| Depreciation and amortization | |||||
| Amortization of intangible assets | |||||
| Amortization of debt discount | |||||
| Accretion of premium on marketable securities, net | |||||
| Realized gain on marketable securities | |||||
| Loss on disposal of equipment | |||||
| Contingent liability fair value measurement adjustment | |||||
| Recognition of deferred revenue | |||||
| Lease payments recognized (deferred) | |||||
| Induced conversion expense related to 2027 and 2028 Convertible Notes | |||||
| Deferred income taxes | |||||
| Other | |||||
| Acquired in-process research and development expense | |||||
| Impairment of intangible asset | |||||
| Changes in operating assets and liabilities | |||||
| Accounts receivable, net and other contract assets | |||||
| Inventories | |||||
| Prepaid expenses and other assets | |||||
| Accounts payable and accrued expenses | |||||
| Net cash provided by operating activities | |||||
| Investing activities | |||||
| Purchases of marketable securities | |||||
| Proceeds from sales and maturities of marketable securities | |||||
| Acquisition of business, net of cash acquired | |||||
| Acquisition of in-process research and development, net of cash acquired | |||||
| Purchases of property and equipment | |||||
| Proceeds from sale of assets | |||||
| Net cash used in investing activities | |||||
| Financing activities | |||||
| Proceeds from term loan | |||||
| Repayment of term loan | |||||
| Proceeds from revolving credit facilities | |||||
| Repayment of revolving credit facilities | |||||
| Proceeds from issuance of 2027 Convertible Notes, net | |||||
| Repayments of Convertible Notes | |||||
| 2024 Convertible Notes | |||||
| 2027 Convertible Notes | |||||
| 2028 Convertible Notes | |||||
| Total repayments of Convertible Notes | |||||
| Proceeds from Convertible Debt | |||||
| 2031 Convertible Notes | |||||
| 2032 Convertible Notes | |||||
| Total proceeds from Convertible Debt | |||||
| Purchase of capped call | |||||
| Payment for the induced conversion of 2027 and 2028 Convertible Notes | |||||
| Premium on repayment of Convertible Notes settled in cash | |||||
| 2027 Convertible Notes | |||||
| 2028 Convertible Notes | |||||
| Purchase of capped calls on 2031 Convertible Notes | |||||
| 2031 Convertible Notes | |||||
| 2032 Convertible Notes | |||||
| Payment of debt issuance cost | |||||
| Repurchase of common stock | |||||
| Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement | |||||
| Net cash used in financing activities | |||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | |||||
| Cash, cash equivalents and restricted cash at beginning of period | |||||
| Cash, cash equivalents and restricted cash at end of period | |||||
| Supplemental disclosure of cash flow information | |||||
| Interest paid | |||||
| Income taxes paid, net | |||||
| Supplemental disclosure of non-cash investing and financing activities | |||||
| Amounts accrued for purchases of property and equipment | |||||
| Right-of-use assets obtained in exchange for lease obligation | |||||
| Common stock issued for conversion of 2024 Convertible Notes | |||||
| Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets | |||||
| Cash and cash equivalents | |||||
| Restricted cash | |||||
Loading...